Thelansis’s “Autosomal Dominant Polycystic Kidney Disease (ADPKD) Emerging Therapy, with Unmet Needs and TPP Insights Report – 2026″ provides a comprehensive analysis of the emerging competitive landscape, unmet needs, target product profiles (TPPs), trial designs, and KOL insights on key emerging therapies and key drug development opportunities in the indication.
Autosomal dominant polycystic kidney disease (ADPKD) is an inherited disorder, usually caused by PKD1 or PKD2 variants, that leads to fluid-filled kidney cysts and progressive enlargement. Symptoms may include hypertension, flank pain, hematuria, kidney stones, or infections, though severity varies. Liver cysts and other extrarenal complications can occur. Some patients develop chronic kidney disease and kidney failure. Management includes blood-pressure control, lifestyle measures, treatment of complications, and monitoring kidney function and progression risk. Tolvaptan can slow kidney-function decline in selected adults at risk of rapid progression, but may cause marked urination, thirst, dehydration, and liver injury, requiring monitoring. Other broadly effective disease-modifying medicines are not established. Investigational approaches include microRNA-targeted oligonucleotides and polycystin-1 correctors such as VX-407, now in Phase 2 testing for selected PKD1 variants.
G8 (United States, EU5 [France, Germany, Italy, Spain, U.K.], Japan, and China)
*Survey is customized based on client requirements
1. Key Findings and Analyst Commentary
2. Competitive Landscape
3. Product Attribute Analysis
4. Primary Market Research
5. Unmet Need and TPP Analysis
6. Regulatory and Reimbursement Environments (by country and payer insights)
7. Appendix (e.g., bibliography, methodology)
No snapshots available.
That depends on the file type you choose: the Excel epidemiology model, the Excel market forecast model with dashboard, and the full analyst report in PowerPoint with a PDF version.
Within 48 to 72 hours of purchase.
Yes. Choose EU5, G7 or G8, or pick individual markets in the panel.
Yes. Request a free sample to preview the scope and sample pages.
Yes. The forecast model is customizable, and our analysts can tailor the scope to your questions.
Yes. Inquire for bundle discounted pricing and we will send you exclusive pricing for the reports you need.
Choose the file type you want to purchase or request.
No file type found.
Select markets to include.
No markets match your search.
Not sure which report fits your question? Our team will point you to the right one.
Tell us what you are looking for and we will tailor the research to your indication, markets and questions.
Prefer to talk it through? Email clientsupport@thelansis.com
You asked for for covering . We will reply to .
Fill in your details and our expert consultants will get in touch with you.
Get a sneak peek at the latest Autosomal Dominant Polycystic Kidney Disease (ADPKD) – Emerging Therapy, with Unmet Needs and TPP Insights Report – 2026 report
Our team will get in touch with you shortly about the Autosomal Dominant Polycystic Kidney Disease (ADPKD) – Emerging Therapy, with Unmet Needs and TPP Insights Report – 2026 report.